

**Boehringer  
Ingelheim****RECEIVED  
CENTRAL FAX CENTER****JUL 25 2006****Boehringer Ingelheim  
Corporation****Telefax**

**TO:** Commissioner for Patents

**DATE:** July 25, 2006

**Fax Number:** 571-273-8300

**Total Number of pages:** 27(including cover sheet)

**Re: Supplemental Response – 9/268**

Attached as per Anthony Bottino's request.

Regards,  
Linda Boland-Covey

Linda Boland-Covey  
Telephone (203) 791-6311  
Telefax (203) 798-4408  
E-Mail lbolandc@rdg.boehringer-  
ingelheim.com

900 Ridgebury Rd/P.O. Box 368  
Ridgefield, CT 06877-0368

THIS COMMUNICATION IS INTENDED ONLY FOR THE PERSON OR ENTITY TO WHOM IT IS ADDRESSED (NAMED ABOVE): THE INFORMATION IT CONTAINS MAY BE CONFIDENTIAL AND/OR LEGALLY PRIVILEGED AND PROTECTED IN LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, IT IS HEREBY STIPULATED THAT ANY COPYING, DUPLICATION OR DISTRIBUTION OF THIS DOCUMENT IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR PLEASE TELEPHONE OR FAX US IMMEDIATELY ON THE NUMBERS SHOWN HERE.

9/268

RECEIVED  
CENTRAL FAX CENTER  
JUL 25 2006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of : COGAN, D., et al ) Art Unit: 1626  
U.S. Appln. No. : 10/718,380 ) Examiner: Shiao, R.T.  
Confirmation No. : 9526  
U.S. Filing Date : 11/20/2003  
Title of Invention : Cytokine Inhibitors  
Attny. Docket No. : 9/268

Via fax 571-273-8300  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL RESPONSE**

Sir:

In response to the office action dated 2/09/2006, applicants submit herewith a  
Supplemental Response to the Response dated 06/06/2006, please reconsider the above-  
identified patent application in view of the following:

**Amendments to the claims** which are reflected in the Current Listing of Claims which  
begin on page 2 of this paper.

**Remarks/Arguments** which begin on page 21 of this paper.